Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,579 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170.
Zinzani PL, Thieblemont C, Melnichenko V, Bouabdallah K, Walewski J, Majlis A, Fogliatto L, Garcia-Sancho AM, Christian B, Gulbas Z, Özcan M, Perini GF, Ghesquieres H, Shipp MA, Thompson S, Chakraborty S, Marinello P, Armand P. Zinzani PL, et al. Among authors: ozcan m. Blood. 2023 Jul 13;142(2):141-145. doi: 10.1182/blood.2022019340. Blood. 2023. PMID: 37130017 Free PMC article. Clinical Trial.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Among authors: ozcan m. J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. J Clin Oncol. 2017. PMID: 28976790 Clinical Trial.
Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J, Hellmann A, Siritanaratkul N, Ozsan GH, Ozcan M, Chuncharunee S, Goh AS, Jurczak W, Koren J, Paszkiewicz-Kozik E, Wang B, Singh S, Huebner D, Engert A, von Tresckow B. Walewski J, et al. Among authors: ozcan m. Br J Haematol. 2018 Nov;183(3):400-410. doi: 10.1111/bjh.15539. Epub 2018 Aug 30. Br J Haematol. 2018. PMID: 30168134 Free article. Clinical Trial.
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Armand P, et al. Among authors: ozcan m. J Clin Oncol. 2019 Dec 1;37(34):3291-3299. doi: 10.1200/JCO.19.01389. Epub 2019 Oct 14. J Clin Oncol. 2019. PMID: 31609651 Free PMC article. Clinical Trial.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Among authors: ozcan m. Am J Hematol. 2020 Apr;95(4):362-371. doi: 10.1002/ajh.25711. Epub 2020 Jan 16. Am J Hematol. 2020. PMID: 31868245 Free article.
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H, Ozbalak M, Karadurmus N, Paydas S, Turker A, Toptas T, Tuglular TF, Altuntas F, Cakar MK, Sonmez M, Gulbas Z, Demir N, Kaynar L, Yildirim R, Karadogan I, Arat M, Kapucu I, Aslan NA, Ozkocaman V, Turgut M, Yuksel MK, Ozcan M, Hacioglu SK, Barista I, Demirkaya M, Saydam G, Toprak SK, Yilmaz M, Demirkol O, Ferhanoglu B. Bekoz H, et al. Among authors: ozcan m. Ann Hematol. 2020 Nov;99(11):2565-2576. doi: 10.1007/s00277-020-04077-4. Epub 2020 Jun 7. Ann Hematol. 2020. PMID: 32507911 Clinical Trial.
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL; KEYNOTE-204 investigators. Kuruvilla J, et al. Among authors: ozcan m. Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, Sapunarova K, Lin T, Jin J, Jurczak W, Hamed A, Wang MC, Baker R, Bondarenko I, Zhang Q, Feng J, Geissler K, Lazaroiu M, Saydam G, Szomor Á, Bouabdallah K, Galiulin R, Uchida T, Soler LM, Cao A, Hiemeyer F, Mehra A, Childs BH, Shi Y, Zinzani PL. Matasar MJ, et al. Among authors: ozcan m. Lancet Oncol. 2021 May;22(5):678-689. doi: 10.1016/S1470-2045(21)00145-5. Epub 2021 Apr 10. Lancet Oncol. 2021. PMID: 33848462 Clinical Trial.
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma.
Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Zinzani PL, et al. Among authors: ozcan m. Blood Adv. 2022 Jan 25;6(2):590-599. doi: 10.1182/bloodadvances.2021004970. Blood Adv. 2022. PMID: 34644372 Free PMC article.
1,579 results